Key Developments: Investor AB (INVEa.ST)

INVEa.ST on Stockholm Stock Exchange

278.90SEK
19 Dec 2014
Price Change (% chg)

2.20kr (+0.80%)
Prev Close
276.70kr
Open
277.40kr
Day's High
279.30kr
Day's Low
274.40kr
Volume
113,209
Avg. Vol
134,515
52-wk High
281.10kr
52-wk Low
199.90kr

Search Stocks

Latest Key Developments (Source: Significant Developments)

Investor AB to Updates on Sale of Gambro to Baxter International Inc
Wednesday, 17 Jul 2013 08:00pm EDT 

Investor AB announced that the regulatory process to get the Gambro transaction cleared by the authorities is moving along, albeit slower than initially estimated. The transaction is now expected to close during the third quarter of 2013. On December 4, 2012, Investor (49%) and EQT (51%), signed an agreement to divest Gambro to the medical technology company Baxter International Inc. for an agreed total enterprise value of SEK 26.5 billion. According to the agreement, Gambro’s equity value will be based on the enterprise value after deduction of the net debt at the closing of the transaction.  Full Article

EU To Clear Baxter International Inc Buy Of Investor AB's Gambro-Reuters
Wednesday, 10 Jul 2013 04:34pm EDT 

Reuters reported that EU antitrust regulators will approve a $4 billion bid by Baxter International Inc for Sweden's Gambro AB after the U.S. company offered to sell a unit that makes up 2% of its renal product sales. Baxter is buying Gambro from Swedish investment holding company Investor AB and its partly owned private equity company EQT.  Full Article

Investor AB Swaps 31% Stake in EQT Partners AB for 19% Ownership Stake in EQT Holdings AB
Tuesday, 4 Jun 2013 02:19am EDT 

Investor AB announced that EQT has established a new corporate structure, which will bring operations, fund administration and investments in general partners together under EQT Holdings AB. The Company will ultimately swap its 31% stake in EQT Partners AB for a 19% ownership stake in the new EQT Holdings AB. This ownership will entitle Investor to receive future dividends from EQT Holdings AB. As before, Investor remains a sponsor and will continue to receive carry from new funds to which Investor commits capital. The new structure does not materially change the total value of Investor’s economic interests in EQT. As before, Investor will not have any influence over the investment decisions made by the individual EQT funds. Investor also stated that the Company’s investments in existing EQT funds are unaffected by the new structure.  Full Article

Investor AB's Growth Capital Sells Entire Stake in Global Health Partner AB-SIX
Thursday, 30 May 2013 09:27am EDT 

SIX reported that Investor AB's Growth Capital has sold the entire stake (9.19 million shares, representing 13.9% of the share capital) in Global Health Partner AB.  Full Article

Investor AB Completes Acquisition of Permobil
Wednesday, 15 May 2013 02:30am EDT 

Investor AB announced that following the approval by the competition authorities, Investor’s acquisition of Permobil, announced on March 27, 2013, has been completed. Permobil will be consolidated as a subsidiary of Investor and reported within Core Investments.  Full Article

Investor AB Elects Deloitte AB as Auditor
Monday, 15 Apr 2013 01:30pm EDT 

Investor AB announced that the Annual General Meeting if the Company elected the registered auditing company Deloitte AB as Auditor of the Company for the period until the end of the Annual General Meeting 2014. Deloitte AB has informed that the Authorized Public Accountant Mr. Thomas Stromberg will be auditor in charge for the audit.  Full Article

Investor AB Acquires Permobil from Nordic Capital Fund V
Wednesday, 27 Mar 2013 10:45am EDT 

Investor AB announced that it has signed an agreement to acquire the Timra (Sweden) based medical technology company Permobil from Nordic Capital Fund V for an enterprise value of SEK 5.1 billion. Permobil is a active in advanced powered wheelchairs. In 2012, sales and EBITDA (pro forma for acquired units) amounted to approximately SEK 1.6 billion and SEK 350 million respectively. Investor expects to inject approximately SEK 3.5 billion in equity financing. The remainder will be financed by external debt and equity participation by the board, management and other key individuals. Subject to the accumulated level of EBITDA during the period between 2013 and 2015, an earn-out payment of a maximum SEK 400 million can be made to Nordic Capital in 2016. For any earn-out to be paid, average annual EBITDA during the period from 2013 and 2015 needs to exceed the current level by at least 25%. After the closing of the transaction, Permobil will be a subsidiary within Investor’s Core Investments. Closing is expected during the second quarter of 2013.  Full Article

Investor AB Announces Details on FY 2012 Dividend
Wednesday, 13 Mar 2013 03:29am EDT 

Investor AB announced that its Board of Directors and the President propose a fiscal year 2012 dividend to the shareholders of SEK 7.00 per share and that April 18, 2013, shall be the record date for receipt of the dividend. Should the Meeting decide in favor of the proposal, payment of the dividend is expected to be made by Euroclear Sweden AB on April 23, 2013.  Full Article

Active Biotech AB Raises SEK 270 Million Through Directed New Issue to Investor AB
Wednesday, 6 Mar 2013 02:30am EST 

Active Biotech AB announced that its Board of Directors has resolved to issue in total 6,000,000 new shares in the Company to Investor AB (publ). The shares are issued at a subscription price of SEK 45 per share, providing the Company with in total approximately SEK 270 million after transaction costs. The closing price for the Active Biotech share on NASDAQ OMX Stockholm on March 5, 2013 was SEK 48.80. The issue proceeds are intended to be used to strengthen Active Biotech's capital base and to enable the continued development and value-growth of the project portfolio. The new issue also strengthens Active Biotech's position in discussions with potential partners. The Board considers it being beneficial for the Company and the shareholders to broaden the shareholder base and to take advantage of the opportunity to raise capital on favorable terms for the Company from a well renowned investor. Active Biotech's two main shareholders MGA Holding AB and Nordstjernan AB, and East Bay AB, with a joint holding of votes and shares of approximately 44%, have stated that they support the new issue. Through the new issue, the number of shares in Active Biotech will increase by 6,000,000 from 68,923,582 to 74,923,582 and the share capital will increase by SEK 22,616,055.93 from SEK 259,796,597.53 to SEK 282,412,653.46. Investor's holding will correspond to approximately 8% of the shares and votes in Active Biotech.  Full Article

Investor AB's EQT IV Sells BTC Group
Friday, 8 Feb 2013 07:45am EST 

Investor AB's EQT IV announced that it has on February 8, 2013 signed an agreement with an affiliate of Sun European Partners, LLP, the European advisor to Sun Capital Partners, Inc., to sell BTX Group (BTX). BTX is a wholesaler comprised of five brands: Brandtex, Jensen Women, Signature, Imitz and Ciso, all of which have their own identity, addressing various sub-segments of the mature women’s wear market. During EQT IV's ownership period, BTX has been through a transformation. Being initially a traditional manufacturing and wholesale company, the company is currently a focused clothing business, targeting the classic mature woman, and having a clear retail-focus, including over 120 shop-in-shops solutions with its broad network of retail partners. While under EQT IV's ownership, the company has taken steps to streamline its operations and create a coherent portfolio of brands, additional potential exists for BTX to further expand its footprint beyond its core Scandinavian market. EQT IV was advised by Carnegie and Plesner. Sun European Partners was advised by Ernst & Young and Horten. Financial details of the transaction were not disclosed.  Full Article

Search Stocks